November 7, 2024 (Lexington, KY) – The Horseracing Integrity and Safety Authority (HISA) has announced an extension to the submission deadline for its <a href="https://bphisaweb.wpengine.com/wp-content/uploads/2024/07/HISA_PED_RFP_Final.pdf">request for proposals</a> (RFP) for research into whether furosemide is a performance-enhancing drug in Thoroughbred racehorses. Originally set for October 15, 2024, the deadline has now been extended to November 22, 2024. This adjustment reflects HISA’s commitment to ensuring that all interested parties have sufficient time to prepare and submit high-quality proposals addressing the complexities of furosemide's effects on horse health and racing performance.
This research is required as part of HISA’s Congressional mandate. The conclusions of this research will be used to guide HISA’s Furosemide Advisory Committee in its recommendations to the HISA Board on next steps regarding the regulation of furosemide.
The <a href="https://bphisaweb.wpengine.com/wp-content/uploads/2024/11/Press-Release-RFP-on-Furosemide-Extension.pdf">application</a> is available on the HISA website and should be submitted via email to Dr. Jennifer Durenberger at jennifer.durenberger@hisaus.org and/or Sam Reinhardt at samuel.reinhardt@hisaus.org.